SOX2 and non-small cell lung carcinoma: In this sense, Chellappan’s research group on 2015, determined SH components, such as GLI1, involved in the SOX2 protein control expression through a GLI1 physical interaction with SOX2 gene promoter sequences, suggesting a key transcriptional role involved in treatment resistance and poor clinical prognosis in NSCLC patients.